Hughes Report: Second Anniversary

Justin Madders Excerpts

Wednesday 11th February 2026 Westminster Hall

[Justin Madders (Ellesmere Port and Bromborough) (Lab)]

It is, as always, a pleasure to see you in the Chair, Dr Allin-Khan, but it is not a pleasure to be here marking two years since the publication of the Hughes report. Sadly, in that time, those recommendations seem to have been in a holding pattern somewhere in the Department for Health and Social Care.

Other Members have rightly spoken about the victims. Today, I think mostly about one of my constituents, who contacted me more than five years ago, raising concerns about the tragic loss of her son when he was 30. She believes that the sodium valproate medication that she took during his pregnancy was responsible for his learning difficulties and, ultimately, his early passing. Quite understandably, she feels let down by the state. She is also concerned about the profound effect that it may have had on her other children, and the fact that she was not alerted to the risks of this by the authorities.

What I find particularly disappointing, having contacted numerous Secretaries of State during that time, is that we have had no more than vague commitments and assurances that this issue will be addressed in due course. That does not cut it for my constituent; nor, sadly, does it do anything to assuage the guilt that she—wrongly, in my opinion—feels.

With other national scandals, such as infected blood and the Post Office Horizon system, the Government have eventually provided funding for mechanisms to compensate those affected, but they too had to wait decades. It is disappointing that the recognition that we all had at the time, that those systems were introduced that those delays had compounded the injustice, has not translated into any visible progress for those harmed by valproate and pelvic mesh.

I agree with the right hon. Member for New Forest East (Sir Julian Lewis) that, in those schemes, the interim payment system has been seen as a way to get at least some measure of redress. I am disappointed that we have not been able to learn from that experience and use a similar system for the people we are talking about today. I have sympathy for the view set out by the Secretary of State that redress must be considered alongside that for other patient groups, but that does not justify inaction.

Those harmed by valproate and pelvic mesh are frustrated by the delays and the obfuscation. The state has acknowledged and apologised for its failings. It has commissioned and published two reports on the matter, both of which have recommended that redress is provided to patients, but we have reached the point where reports and recommendations are not enough. It is time for the Government to act, and to provide the support that the many victims of this scandal deserve and need to manage their ongoing conditions. The can has been kicked down the road for too long; campaigners and those affected are understandably frustrated and anxious for change.

I would like to ask the Minister two things, echoing the questions raised by the hon. Member for Chesham and Amersham (Sarah Green). First, can the Minister confirm whether there has been an estimate of the total cost of providing redress? If so, can she share that today? That might, at least, give campaigners some hope that things are actually moving forward. Secondly, can she confirm whether she has discussed funding redress with the Treasury for inclusion in future fiscal events? I look forward to the Minister’s response—or, if she is unable to provide specific answers today, to a commitment that she or a colleague will do so in future, and a clear sense those who have suffered are now being listened to.

[Several hon. Members rose—]